AIM ImmunoTech Inc. has released its financial results for the second quarter of 2025. The company reported cash, cash equivalents, and marketable investments totaling $835,000 as of June 30, 2025. Meanwhile, research and development expenses increased to $1.2 million from $1.1 million in the same period in 2024. General and administrative expenses decreased significantly to $1.5 million from $2.6 million for the same period in the previous year. AIM recorded a net loss from operations of $2.8 million, compared to $1.8 million in the second quarter of 2024. The company highlighted continued progress in its pipeline programs, with a focus on pancreatic cancer. AIM provided a mid-year report on Ampligen® in combination with AstraZeneca's Imfinzi® for pancreatic cancer treatment, showing promising progress with no significant toxicity and improved progression-free survival $(PFS)$ and overall survival $(OS)$. AIM also reported a bolstered cash position, expected to fund operations for approximately 12 months, following an $8.0 million public equity offering closed in July. Recent corporate highlights include the resumption of trading on the NYSE American and positive data from the Phase 2 DURIPANC clinical study.